



Office de la Propriété  
Intellectuelle  
du Canada  
Un organisme  
d'Industrie Canada

Canadian  
Intellectual Property  
Office  
An agency of  
Industry Canada

CA 2465382 A1 2003/05/08

(21) **2 465 382**


(12) **DEMANDE DE BREVET CANADIEN  
CANADIAN PATENT APPLICATION**

(13) **A1**

(86) Date de dépôt PCT/PCT Filing Date: 2002/10/29  
(87) Date publication PCT/PCT Publication Date: 2003/05/08  
(85) Entrée phase nationale/National Entry: 2004/04/29  
(86) N° demande PCT/PCT Application No.: JP 2002/011234  
(87) N° publication PCT/PCT Publication No.: 2003/037864  
(30) Priorité/Priority: 2001/10/29 (2001-331501) JP

(51) Cl.Int.<sup>7</sup>/Int.Cl.<sup>7</sup> C07D 209/42, A61K 31/553,  
A61K 31/5513, A61K 31/537, A61K 31/536, A61P 43/00,  
A61K 45/00, A61K 31/517, A61K 31/497, A61K 31/4439,  
A61K 31/427, A61K 31/4196, ...  
(71) Demandeur/Applicant:  
JAPAN TOBACCO INC., JP  
(72) Inventeurs/Inventors:  
NAKAMURA, TAKESHI, JP;  
TAKAGI, MASAKI, JP;  
UEDA, NOBUHISA, JP  
(74) Agent: FETHERSTONHAUGH & CO.

(54) Titre : COMPOSE INDOLIQUE, ET UTILISATION A DES FINS THERAPEUTIQUES  
(54) Title: INDOLE COMPOUND AND MEDICINAL USE THEREOF



(57) Abrégé/Abstract:

An indole compound represented by the general formula (1): (1) (wherein the symbols are the same as defined in the description) and a pharmaceutically acceptable salt or prodrug thereof. These are useful as a diabetes remedy having HGLP<sub>α</sub> inhibitory activity.



(51) Cl.Int.<sup>7</sup>/Int.Cl.<sup>7</sup> (suite/continued) A61K 31/4188, A61K 31/4178, A61K 31/4155, A61K 31/41, A61K 31/407, A61K 31/404, A61P 3/10, A61K 45/06, C07D 495/04, C07D 487/04, C07D 409/04, C07D 401/12, C07D 405/12, C07D 403/12, C07D 409/14, C07D 401/14, C07D 417/12, C07D 413/12, C07D 409/12